CVL-871 is under clinical development by Cerevel Therapeutics and currently in Phase II for Dementia. According to GlobalData, Phase II drugs for Dementia have a 55% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CVL-871’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CVL-871 is under development for the treatment of dementia related apathy. It acts by targeting dopamine 1 (D1) and dopamine 5 receptor (D5). It is administered through oral route. The drug candidate was also under development for Parkinson's disease.
Cerevel Therapeutics overview
Cerevel Therapeutics is a biopharmaceutical company which develops and commercializes medicines for the treatment of central nervous system disorders. The company is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of CVL-871’s drug-specific PTSR and LoA scores, buy the report here.